Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.

This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.

Key clinical takeaways:

• mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
• Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
• Choice of 2nd line treatment should be guided by prior regimen and patient fitness
• Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0

Or watch on YouTube: https://youtu.be/8YxRnjOYUv4

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/giconnect

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen USA.

This podcast is developed by cor2ed.com

Published May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.

As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.

Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.

What does the patient pathway look like from both perspectives? What are the needs of Medical Oncologists and patients when navigating the treatment journey? What do patients need from their oncologists? What do oncologists think their patients need from them? Are these needs matched by the support currently available?

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.

The conversation unfolds to cover;

• How to distinguish HER2 alterations from other alterations on biomarker reports

• The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC

• The potential CNS activity of these treatments in patients with HER2-mutated NSCLC

• How the treatment pathway may look in the near future

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/

Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives

This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.

What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos.

In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting.

Listen to different expert perspectives on

• The different HER2 alterations and prevalence in NSCLC

• Which technique to identify which HER2 alteration

• HER2-targeted treatments, both approved and in development

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1

Or watch on YouTube: https://youtu.be/3vMCzR1jqbI

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published on April 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups.

Key topics include

• Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET

• Clinical implications of the EMERALD post-hoc subgroup analyses

• Review of elacestrant's safety profile

Clinical takeaways

• Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer

• The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N

• Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors

• These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.

This video was developed by https://cor2ed.com/

Published March 2025

This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.

Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.

Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.

Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.

Key clinical takeaways:

• Molecular testing, especially for biomarkers like ESR1 and PI3 kinase, is a critical component in guiding treatment decisions, particularly in second-line therapy for HR+ HER2- metastatic breast cancer.

• Liquid biopsy is a valuable tool for ongoing monitoring of metastasis and detecting mutations like ESR1 during disease progression, but tissue biopsies may yield more reliable results for certain mutations like PI3 kinase alterations present early in cancer development.

• Testing for a broad range of mutations, such as PI3 kinase, AKT, PTEN, ESR1, MSI, and NTRK, allows for the identification of actionable mutations and eligibility for newer targeted therapies, especially in second and third-line treatments.

• Clinicians must be familiar with the specifics of the assays used to test for mutations, as different methods and testing conditions can impact results.

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/ntrk-connect/

X: https://x.com/PresOnc_Connect

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.

This podcast is developed by cor2ed.com

Published March 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Key clinical takeaways:

• MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions

• ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations

• Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting

• Shared decision-making, supported by patient education, is essential for optimising treatment outcomes

The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC.

Key topics include:

• The role of molecular classification in guiding treatment selection and testing strategies

• Treatment options for patients with pMMR status

• Effective patient communication for shared decision-making

Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/

Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true

X: https://x.com/OBGynConnect

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast.

This podcast is developed by cor2ed.com

Published February 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Intermediate HCC – The evolving role of IO

In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.

Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC.

Key clinical takeaways:

• IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden

• Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited

• Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC

You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/

Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect/

X https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.

This podcast is developed by cor2ed.com

Published on January 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. <...